CONTACT US: Contact info
|
Citation |
Grov C, Westmoreland DA, D'Angelo AB, Johnson J, Nash D, Daskalakis DC, Together 5000 team. AIDS Behav. 2020; ePub(ePub): ePub. |
|
Copyright |
(Copyright © 2020, Holtzbrinck Springer Nature Publishing Group) |
|
DOI |
|
PMID |
32729019 |
|
Abstract |
There has been an influx of ads on social media seeking plaintiffs in lawsuits for harms/side-effects caused by tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC, Truvada) for PrEP. Community groups and researchers have suggested these ads may be undermining efforts to disseminate PrEP to key populations. In October 2019, we began assessing the impact of injury lawsuit ads on social media platforms in an ongoing U.S. national cohort study of HIV-negative cis men, trans men, and trans women who have sex with men. Although assessments are ongoing, given the alarming nature of our findings, we report data collected as of March 2020 (n = 2078). Most (59.9%) said they had seen ads for TDF-related lawsuits on social media. Twenty-eight percent said they would probably or definitely not start PrEP and 22.1% said they would not stay on PrEP (were they on it) as a result of seeing these ads. Next, 38.2% agreed or strongly agreed that seeing these ads made them think that TDF/FTC for PrEP was not safe. Black, Latinx, and/or multiracial individuals were most likely to be negatively impacted by the ads including perceptions that these ads made them think PrEP is not safe. In contrast, past year experience taking PrEP was positively associated with intentions to start and/or stay on PrEP despite seeing the ads. Due to forthcoming affordable/generic options, TDF/FTC is projected to become the most scalable option for disseminating PrEP to key populations. Language: en |
|
Keywords |
Social media; Gay and bisexual men; Lawsuits; PrEP; Tenofovir alafenamide; Tenofovir disoproxil fumarate |